Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Debu Tripathy, MD on the importance of cdk4/6 for future breast cancer treatments

Debu Tripathy, MD, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center weighs in on how important a role cdk4/6 inhibitors will play in future breast cancer treatments

Published: 08 November 2016

Recent Videos: Breast

video

Neelima Denduluri, MD, considers whether the results of TAILORx are practice-changing

Dr. Denduluri offers opinion on the practice-changing results of the TAILORx study presented at the 2018 ASCO Annual Meeting

video

Neelima Denduluri, MD, on the MONALEESA-3 study in HR+/HER2- advanced breast cancer

Dr. Denduluri elaborates on the significance of the improvement in the PFS fulvestrant +ribociclib arm of the MONALEESA-3 study in ...

video

Neelima Denduluri, MD, speculates on the implications of taselisib data at ASCO 2018

Dr. Denduluri offers opinion on whether taselisib might one day become a standard of care based on the outcomes of ...

video

Julie Gralow, MD, speaks to the significance of the MONALEESA-3 study

Dr. Gralow regarding the improvement in PFS fulvestrant + ribociclib arm of the MONALEESA-3 study in HR+/HER2- advanced breast cancer

video

Julie Gralow, MD, on the implications of the PERSEPHONE trial in early HER2+ breast cancer

Dr. Gralow regarding the results of the PERSEPHONE trial in early HER2+ breast cancer presented at the 2018 ASCO Annual ...

video

Julie Gralow, MD, reflects on the PERSEPHONE trial from the 2018 ASCO Annual Meeting

Dr. Gralow puts the PERSEPHONE trial into context with the ShortHER trial from the 2017 ASCO Annual Meeting as well ...

video

Julie Gralow, MD, regarding the reduction in cardiac events in the PERSEPHONE study

Dr. Gralow on whether the reduction of cardiac events in the PERSEPHONE study comparing 6 months versus 12 months of ...

video

Julie Gralow, MD, discusses outcomes from the TAILORx study presented at ASCO 2018

Dr. Gralow on whether the TAILORx study in HR+, HER2-, node-negative, intermediate 21-gene recurrence score patients tells us endocrine therapy ...

video

Julie Gralow, MD, comments on the practice-changing implications of the TAILORx study

Dr. Gralow shares her thoughts on the practice-changing TAILORx study in HR+, HER2-, node-negative, intermediate 21-gene recurrence score patients

video

Julie Gralow, MD, tells us about the SANDPIPER proof of concept trial presented at ACSO 2018

Dr. Gralow considers the SANDPIPER study presented at the 2018 ASCO Annual Meeting and whether adding taselisib to fulvestrant in ...

Related Videos

video-image

Neelima Denduluri, MD, speculates on the implications of taselisib data at ASCO 2018

video-image

Neelima Denduluri, MD, on the MONALEESA-3 study in HR+/HER2- advanced breast cancer

video-image

Neelima Denduluri, MD, considers whether the results of TAILORx are practice-changing

video-image

Julie Gralow, MD, speculates on taselisib as a standard of care based on the results of SANDPIPER

video-image

Julie Gralow, MD, tells us about the SANDPIPER proof of concept trial presented at ACSO 2018

video-image

Julie Gralow, MD, comments on the practice-changing implications of the TAILORx study

video-image

Julie Gralow, MD, discusses outcomes from the TAILORx study presented at ASCO 2018

video-image

Julie Gralow, MD, regarding the reduction in cardiac events in the PERSEPHONE study

video-image

Julie Gralow, MD, reflects on the PERSEPHONE trial from the 2018 ASCO Annual Meeting

video-image

Julie Gralow, MD, on the implications of the PERSEPHONE trial in early HER2+ breast cancer

video-image

Julie Gralow, MD, speaks to the significance of the MONALEESA-3 study

video-image

Julie Gralow, MD, elaborates on how to differentiate CDK4/6 inhibitors

video-image

Douglas W. Blayney, MD, discusses the biggest takeaway regarding breast cancer here at ASCO 2018

video-image

Douglas W. Blayney, MD, on if the results of the TAILORx study practice changing

video-image

Douglas W. Blayney, MD, discusses the implications of the TAILORx study

video-image

Douglas W. Blayney, MD, discusses the MONALEESA-3 study in HR+/HER2- advanced breast cancer

video-image

Douglas W. Blayney, MD, on differentiating CDK4/6 Inhibitors and if they can be used interchangeably

video-image

Sara M. Tolaney, MD, MPH on whether CDK4/6 inhibitors can be used interchangeably

video-image

Sara M. Tolaney, MD, MPH tells us about the outcomes of the MONARCH 2 study

video-image

Sara M. Tolaney, MD, MPH discusses the practice changing outcomes of the TAILORx study

video-image

Sara M. Tolaney, MD, MPH, discusses the fulvestrant + ribociclib arm of the MONALEESA-3 study

video-image

Sara M. Tolaney, MD, MPH, on whether the results of the TAILORx study are “practice changing”